Resources
15 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 3/25/2021 (updated 4/5/2024)
Recovery Housing, Medications for OUD (MOUD), and Emerging Issues
Presenters will explain recovery housing and MOUD in the context of issues emerging in rural America resulting from the pandemic and its impact on the rates of substance use disorder (SUD) and drug overdose. They will discuss the impact of the pandemic on the correctional system and state actions in response to COVID-19 as it affects those with SUD. They will also give an overview of how recovery housing can be developed, especially in rural areas.
Posted 11/11/2021 (updated 4/3/2024)
This session presented resources and elements to consider when planning to collaborate with a local jail to establish pre- and post-release programing and coordination of care and services for individuals with SUD. A real-world example was presented by an RCORP grantee showcasing its First Day Forward Program.
Posted 10/14/2021 (updated 4/3/2024)
Rural Community Opioid Response Program (RCORP) grantees discussed their efforts and initiatives working with criminal justice and corrections agencies to engage individuals who are incarcerated.
Posted 11/11/2020 (updated 4/3/2024)
This report describes decedent demographic characteristics and circumstances surrounding overdose deaths during January–June 2019 among 25 jurisdictions participating in CDC’s State Unintentional Drug Overdose Reporting System (SUDORS),† and it highlights the involvement of opioids and stimulants, separately and in combination.
Posted 8/11/2020 (updated 4/2/2024)
Non-fatal opioid overdose (NFOO) is a significant cause of opioid-related morbidity in the United States. As the number of NFOOs continues to grow, it is important to understand the short- and long-term consequences of NFOO. This report examines the existing literature on the acute and chronic health and functional outcomes of individuals who experience NFOO, and also identifies differences in outcomes for NFOOs involving illicitly-manufactured fentanyl.
Posted 8/4/2021 (updated 4/2/2024)
Posted 9/4/2020 (updated 3/29/2024)
The analysis examined syndromic surveillance data from 2018–2019 in 29 states for suspected nonfatal drug and polydrug overdoses treated in emergency departments.
Posted 7/26/2023 (updated 3/28/2024)
Just 5 years ago, only 1% of jails and prisons provided MOUD, but this practice has flourished. Dr. Costello discussed the emerging evidence base for MOUD in jails, regulatory changes, funding opportunities, and the dramatic increase in usage of MOUD in our nation's correctional facilities.
Posted 7/26/2023 (updated 3/28/2024)
This presentation provided an overview of the (1) current U.S. prevalence of opioid abuse and OUD and their societal consequences, (2) impacts of the opioid epidemic on rural geographic areas and populations, (3) recent emergence of synthetic opioids (e.g., fentanyl) and xylazine in the U.S. drug supply, and (4) most empirically supported treatment for patients with OUD.
Posted 7/14/2023 (updated 3/28/2024)
The Centers for Disease Control and Prevention released data showing a significant increase – 276 percent in 21 jurisdictions from 2019 to 2022 – in overdose deaths involving Xylazine, a nonopioid sedative that’s been detected in illicitly manufactured fentanyl drug products.